MarketCap
Facebook
X
Telegram
MEI Pharma Income Statement 2025-2002 | MEIP
Brief overview of financial performance at MEI Pharma
This overview is based on financial performance over the past five years. The revenue attributed to MEI Pharma moved from 4.9 million dollars to 65.3 million dollars between the two endpoints. Across the full period, sales moved by +1228.5%; the average annual rate was 67.8%. This pace points to rapid expansion of the business.
The five-year EBITDA result moved by +132.3%: from −46.2 million dollars to 14.9 million dollars. Operating performance weakened relative to revenue. The EBITDA share of revenue changed from −939.3% to 22.9%. The business generated more EBITDA from each unit of revenue.
Comparing the endpoints shows a move from −16.8 million dollars to 17.8 million dollars. The trajectory reversed from a loss to positive earnings.
Financial takeaway
The indicators form a favorable picture of business development. Key strengths include improving net profitability, a larger revenue base and an improving EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement MEI Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
20.5 M | 20.9 M | 48.9 M | 3.3 M | 225 M | 273 M | 124 M | 152 M | 109 M | 46.8 M | 45.1 M | 137 M | 75.9 M | 5.53 M | 16.6 M | - | - | - | - | - | - | - | - | - |
Shares |
6.66 M | 6.66 M | 6.66 M | 6.22 M | 113 M | 91.1 M | 71.1 M | 41.4 M | 36.8 M | 34.4 M | 28.2 M | 20.1 M | 10.2 M | 2.25 M | 1.27 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
3.07 | 3.14 | 7.34 | 0.53 | 2.16 | 3.75 | 1.93 | 2.88 | 2.22 | 1.69 | 1.16 | 5.89 | 8.63 | 7.45 | 5.16 | - | - | - | - | - | - | - | - | - |
Net Income |
-15.9 M | 17.8 M | -32 M | -54 M | -41.3 M | -47.2 M | -16.8 M | -40.1 M | 2.67 M | -20.9 M | -32.7 M | -27.1 M | -11.2 M | -7.52 M | -6.78 M | -7.9 M | -11.2 M | -12.4 M | -13.8 M | -7.39 M | -6.42 M | -8.54 M | -3.03 M | -123 K |
Revenue |
- | 65.3 M | 48.8 M | 40.7 M | 34.8 M | 27.8 M | 4.92 M | 1.62 M | 23.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | 1.41 M | 2.67 M | 4.26 M | 3.38 M | 5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 652 K | -1.76 M | 18.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-17.5 M | 14.5 M | -36.8 M | -75.5 M | -60.4 M | -25.7 M | -46.2 M | -28.6 M | 2.38 M | -21 M | -32.8 M | -27.2 M | -11.2 M | -8.39 M | -6.45 M | - | - | - | - | - | - | - | - | - |
Interest Expense |
-16 K | -41 K | -22 K | -6 K | 486 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-17.1 M | 14.9 M | -36.4 M | -75.2 M | -60.1 M | -25.6 M | -46.2 M | -28.5 M | 2.47 M | -20.9 M | -32.7 M | -27.2 M | -11.2 M | -8.38 M | -6.44 M | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | 46.9 M | 26.8 M | 15.9 M | 21 M | 32.8 M | 27.2 M | 11.2 M | 8.39 M | 6.45 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
13.5 M | 23.3 M | 33.1 M | 30.5 M | 24.4 M | 16.7 M | 14.6 M | 9.79 M | 8.63 M | 5.67 M | 7.18 M | 6.45 M | 5.14 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement MEI Pharma
| 2026-Q3 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
35.7 M | 37.4 M | 29.5 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.66 M | 6.65 M | 127 M | 113 M | 116 M | 113 M | 113 M | 112 M | 113 M | 112 M | 78.6 M | 73.6 M | 78.6 M | 71.2 M | 71.1 M | 70.9 M | 71.1 M | 37.4 M | 37.4 M | 37.2 M | 37.4 M | 37.2 M | 37.2 M | 35.7 M | 37.2 M | 34.4 M | 34.4 M | 34.3 M | 34.4 M | 34.3 M | 23.6 M | 21.7 M | 23.6 M | 21.7 M | 20.1 M | 17.1 M | 20.1 M | 17.1 M | 5.46 M | 3.5 M | 5.46 M | 21 M | 1.98 M | 9.59 M | 8.88 M | 8.88 M |
Net Income |
-23.7 M | -30.8 M | -3.64 M | - | -2.57 M | -2.68 M | -8.01 M | - | -9.13 M | -11.1 M | 56.4 M | - | -15.4 M | 10.3 M | -16.6 M | -6.37 M | -8.72 M | -12.2 M | -17.5 M | -29.7 M | -17.5 M | -8.03 M | -11.5 M | -11.5 M | -2.09 M | -20.2 M | -20.2 M | -20.2 M | -2.99 M | 12 M | 12 M | 12 M | -14.5 M | -6.08 M | -8.79 M | -6.08 M | -8.79 M | 11.9 M | -4.27 M | 11.9 M | -4.27 M | -5.1 M | -4.62 M | -5.1 M | -4.62 M | -9.11 M | -8.99 M | -9.11 M | -8.99 M | -6.32 M | -4.9 M | -3.22 M | -2.75 M | -2.75 M | -2.46 M | -2.75 M | -2.46 M | -1.54 M | -1.61 M | -1.54 M | -1.61 M |
Revenue |
- | - | - | - | - | - | - | - | - | - | 65.3 M | - | 5.89 M | 32.7 M | 8.73 M | 41.5 M | 9.69 M | 11.8 M | 7.76 M | 19.6 M | 13.4 M | 12.6 M | 6.64 M | 9.17 M | 3.83 M | 1.01 M | 1.16 M | 1.01 M | 1.16 M | 2.05 M | 488 K | 2.05 M | 488 K | 358 K | 283 K | 358 K | 283 K | 17.2 M | 1.1 M | 17.2 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
548 K | 499 K | - | - | - | 2.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 405 K | 494 K | 509 K | 494 K | 509 K | 641 K | 688 K | 641 K | 688 K | 1.01 M | 989 K | 1.01 M | 989 K | 728 K | 618 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-21.6 M | -29.9 M | -3.74 M | - | -2.77 M | -3.45 M | -8.35 M | - | -9.83 M | -11.9 M | 55.3 M | - | -16.4 M | 8.93 M | -18.2 M | -9.29 M | -21.6 M | -17.6 M | -20.1 M | -37.7 M | -14.5 M | -15.8 M | -12.8 M | -19.2 M | -15.6 M | -12.1 M | -12.6 M | -12.1 M | -12.6 M | -11.8 M | -10 M | -11.8 M | -10 M | -6.17 M | -8.89 M | -6.17 M | -8.89 M | 11.8 M | -4.32 M | 11.8 M | -4.32 M | -5.13 M | -4.65 M | -5.13 M | -4.65 M | -9.12 M | -9 M | -9.12 M | -9 M | -6.35 M | -4.91 M | -6.35 M | -4.91 M | -2.76 M | -2.47 M | -2.76 M | -2.47 M | -1.96 M | -1.93 M | -3.89 M | -1.93 M |
Interest Expense |
- | - | - | - | -1 K | -5 K | -10 K | - | -4 K | -2 K | -1 K | - | -4 K | -4 K | -2 K | -6 K | - | - | 482 K | - | -13 K | 500 K | -1 K | 495 K | - | 13 K | -1 K | 13 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-21.6 M | - | - | - | - | - | -7.98 M | - | - | -11.8 M | 55.4 M | - | - | 9.02 M | -18.1 M | -9.1 M | -21.6 M | -17.6 M | -20 M | -37.6 M | -14.4 M | -15.8 M | -12.7 M | -19.1 M | -15.5 M | -12.1 M | -12.6 M | -12 M | -12.6 M | -11.8 M | -10 M | -11.8 M | -10 M | -6.17 M | -8.87 M | -6.14 M | -8.87 M | 11.8 M | -4.31 M | 11.8 M | -4.31 M | -5.13 M | -4.63 M | -5.1 M | -4.63 M | -9.12 M | -8.99 M | -9.09 M | -8.99 M | -6.35 M | -4.9 M | -6.32 M | -4.9 M | -2.76 M | -2.46 M | -2.74 M | -2.46 M | -1.96 M | -1.93 M | -3.88 M | -1.92 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.41 M | 5.13 M | 4.65 M | 9.77 M | 8.96 M | 9.12 M | 9 M | 9.12 M | 9 M | 6.35 M | 4.91 M | 6.35 M | 4.91 M | 2.76 M | 2.47 M | 2.76 M | 2.47 M | 1.96 M | 1.93 M | 3.89 M | 1.93 M |
General and Administrative Expenses |
2.74 M | 3.3 M | 3.1 M | - | 2.4 M | 3.14 M | 5.19 M | - | 4.61 M | 8.02 M | 6.53 M | - | 7.18 M | 8.5 M | 7.49 M | 16 M | 8.93 M | 7.93 M | 7.91 M | 15.8 M | 7.91 M | 5.65 M | 5.92 M | 5.65 M | 5.92 M | 4.2 M | 4.13 M | 4.2 M | 4.13 M | 3.82 M | 3.4 M | 3.82 M | 3.4 M | 2.36 M | 2.49 M | 2.36 M | 2.49 M | 1.97 M | 2.68 M | 1.97 M | 2.68 M | 1.94 M | 1.83 M | 1.94 M | 1.83 M | 2.42 M | 2.44 M | 2.42 M | 2.44 M | 1.95 M | 1.81 M | 1.95 M | 1.81 M | 1.42 M | 914 K | 1.42 M | 914 K | 896 K | 889 K | 1.78 M | 889 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company MEI Pharma (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
